HGG-51. Uncovering therapeutic vulnerabilities in mismatch repair-deficient gliomas

INTRODUCTION: We have observed that approximately 26% of recurrent gliomas acquire hypermutation following treatment with temozolomide (TMZ). Intriguingly, 91% of these tumors harbor mutations in mismatch repair (MMR) genes. Since MMR deficiency confers resistance to TMZ, strategies to target MMR-de...

Descripción completa

Detalles Bibliográficos
Autores principales: Boynton, Adam, Pal, Sangita, Johnston, Ryan, Currimjee, Naomi, Qian, Kenin, Touat, Mehdi, Persky, Nicole, Goodale, Amy, Berstler, James, Miller, Lisa, Guletsky, Alex, Ligon, Keith L, Beroukhim, Rameen, Bandopadhayay, Pratiti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
High Grade Glioma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164872/
http://dx.doi.org/10.1093/neuonc/noac079.266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164872/
http://dx.doi.org/10.1093/neuonc/noac079.266

Ejemplares similares